Chan SL - Search Results

1

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.

Lee MMP, Chan LL, Chan SL. Lee MMP, et al. Among authors: chan ll, chan sl. J Liver Cancer. 2023 Sep;23(2):262-271. doi: 10.17998/jlc.2023.07.17. Epub 2023 Aug 17. J Liver Cancer. 2023. PMID: 37589044 Free PMC article.

2

Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma.

Chan SL, Mo FK, Wong VW, Liem GS, Wong GL, Chan VT, Poon DM, Loong HH, Yeo W, Chan AT, Mok TS, Chan HL. Chan SL, et al. Among authors: chan vt, chan hl, chan at. Liver Int. 2012 Feb;32(2):271-8. doi: 10.1111/j.1478-3231.2011.02634.x. Epub 2011 Aug 31. Liver Int. 2012. PMID: 22098536

3

A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma.

Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, Ma BB, Chan AT, Mok TS, Yeo W. Chan SL, et al. Among authors: chan cm, chan at. Cancer. 2012 Aug 15;118(16):3984-92. doi: 10.1002/cncr.26726. Epub 2011 Dec 16. Cancer. 2012. PMID: 22180222 Free article.

4

Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response.

Yeo W, Chan SL, Mo FK, Chu CM, Hui JW, Tong JH, Chan AW, Koh J, Hui EP, Loong H, Lee K, Li L, Ma B, To KF, Yu SC. Yeo W, et al. Among authors: chan sl, chan aw. BMC Cancer. 2015 May 12;15:395. doi: 10.1186/s12885-015-1334-6. BMC Cancer. 2015. PMID: 25962426 Free PMC article. Clinical Trial.

5

Personalized therapy for hepatocellular carcinoma: Where are we now?

Chan SL, Wong AM, Lee K, Wong N, Chan AK. Chan SL, et al. Among authors: chan ak. Cancer Treat Rev. 2016 Apr;45:77-86. doi: 10.1016/j.ctrv.2016.02.008. Epub 2016 Mar 2. Cancer Treat Rev. 2016. PMID: 26995632 Review.

6

Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance.

Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Fox R, Yeo W, Mo F, Lai P, Chan SL, Tada T, Toyoda H, Kumada T. Johnson P, et al. Among authors: chan sl. Br J Cancer. 2017 Feb 14;116(4):441-447. doi: 10.1038/bjc.2016.422. Epub 2017 Jan 12. Br J Cancer. 2017. PMID: 28081537 Free PMC article.

7

Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?

Margetts J, Ogle LF, Chan SL, Chan AWH, Chan KCA, Jamieson D, Willoughby CE, Mann DA, Wilson CL, Manas DM, Yeo W, Reeves HL. Margetts J, et al. Among authors: chan awh, chan kca, chan sl. Br J Cancer. 2018 Jan;118(2):248-257. doi: 10.1038/bjc.2017.386. Epub 2017 Nov 9. Br J Cancer. 2018. PMID: 29123264 Free PMC article.

8

Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma.

Cheung TT, Kwok PC, Chan S, Cheung CC, Lee AS, Lee V, Cheng HC, Chia NH, Chong CCN, Lai TW, Law ALY, Luk MY, Tong CC, Yau TCC. Cheung TT, et al. Liver Cancer. 2018 Mar;7(1):40-54. doi: 10.1159/000485984. Epub 2018 Jan 25. Liver Cancer. 2018. PMID: 29662832 Free PMC article.

9

Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.

Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX. Galle PR, et al. Among authors: chan sl. Liver Int. 2019 Dec;39(12):2214-2229. doi: 10.1111/liv.14223. Epub 2019 Sep 11. Liver Int. 2019. PMID: 31436873 Review.

10

Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.

Chan LL, Chan SL. Chan LL, et al. Among authors: chan sl. Expert Opin Emerg Drugs. 2021 Mar;26(1):39-52. doi: 10.1080/14728214.2021.1902503. Epub 2021 Mar 19. Expert Opin Emerg Drugs. 2021. PMID: 33724135 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

670 results

Search Page